Examkin

Question

Difficulty: HardInfectious Diseases

A 61-year-old female is evaluated in the hospital on day 4 of admission for a non-healing right foot ulcer. She has a 15-year history of type 2 diabetes mellitus complicated by severe peripheral neuropathy. On admission, she presented with localized erythema, warmth, and purulent drainage from a deep plantar ulcer. A probe-to-bone test was positive. She was hemodynamically stable with no signs of systemic inflammatory response syndrome. A deep bone biopsy was obtained for culture, and she was empirically started on intravenous vancomycin and piperacillin-tazobactam.

Today, her erythema has significantly improved. She remains afebrile and hemodynamically stable. The bone biopsy culture results are now available, demonstrating heavy growth of two organisms. Blood cultures show no growth.

The antimicrobial susceptibility report is as follows:

Antimicrobial*Proteus mirabilis**Bacteroides fragilis*
AmpicillinResistantNot tested
CefazolinResistantNot tested
CeftriaxoneSusceptibleNot tested
CiprofloxacinResistantNot tested
ClindamycinNot testedResistant
MetronidazoleNot testedSusceptible
MeropenemSusceptibleSusceptible
Piperacillin-tazobactamSusceptibleSusceptible

Based on these results, which of the following is the most appropriate next step in this patient's antimicrobial management?

  1. A
    Discontinue vancomycin and continue piperacillin-tazobactam.
  2. B
    Discontinue current antibiotics and initiate meropenem.
  3. Discontinue current antibiotics and initiate ceftriaxone and metronidazole.Answer
  4. D
    Continue the current empiric regimen of vancomycin and piperacillin-tazobactam.
  5. E
    Discontinue current antibiotics and initiate ciprofloxacin and metronidazole.

Answer

Discontinue current antibiotics and initiate ceftriaxone and metronidazole.
The patient has diabetic foot osteomyelitis. Her bone culture grew Proteus mirabilis (a Gram-negative rod) and Bacteroides fragilis (an obligate anaerobe). Antimicrobial stewardship principles dictate that once culture and susceptibility data are available, broad-spectrum empiric therapy should be de-escalated to the narrowest-spectrum effective regimen. P. mirabilis is susceptible to ceftriaxone, which is a third-generation cephalosporin with a narrower spectrum than piperacillin-tazobactam or meropenem (it lacks anti-pseudomonal activity). B. fragilis is susceptible to metronidazole, a targeted anaerobic agent. Therefore, the combination of ceftriaxone and metronidazole provides optimal, targeted coverage for both isolated pathogens while minimizing collateral damage to the microbiome.

Step-by-Step Solution

1
Identify the clinical diagnosis and the organisms isolated.
The patient has diabetic foot osteomyelitis caused by Proteus mirabilis and Bacteroides fragilis.
A positive probe-to-bone test in a deep diabetic ulcer indicates osteomyelitis, which is confirmed by heavy growth on deep bone biopsy culture.
2
Analyze the antimicrobial susceptibility data for both organisms.
P. mirabilis is susceptible to ceftriaxone, meropenem, and piperacillin-tazobactam, but resistant to ampicillin, cefazolin, and ciprofloxacin. B. fragilis is susceptible to metronidazole, meropenem, and piperacillin-tazobactam.
Selecting an effective regimen requires matching the susceptibility profiles of all isolated pathogens.
3
Apply antimicrobial stewardship principles to select the optimal definitive therapy.
Ceftriaxone (for P. mirabilis) plus metronidazole (for B. fragilis) is selected.
This combination is the narrowest-spectrum regimen that effectively treats both organisms, avoiding the unnecessary use of anti-pseudomonal agents or carbapenems.

Key Concept

In patients with polymicrobial infections, empiric broad-spectrum antibiotics should be de-escalated to the narrowest-spectrum regimen effective against all isolated organisms to promote antimicrobial stewardship and prevent resistance.
Rate this question

Topics

Infectious Diseases

More questions from this topic